1) R. Nakamura, M. Konishi, M. Taniguchi, Y. Hatakawa, T. Akizawa, The discovery of shorter synthetic proteolytic peptides derived from Tob1 protein. Peptides, 116, 71–77 (2019).
2) R. Nakamura, M. Konishi, Y. Hatakawa, M. Saito, T. Akizawa, The novel catalytic peptide, a synthetic nona-peptide (JAL-TA9) derived from Tob1 protein, digests the amyloid-β peptide. J. Royal, Sci., 1, 30–35 (2019)
3) R. Nakamura, M. Konishi, Y. Higashi, M. Saito, T. Akizawa, Comparison of the catalytic activities of 5-mer synthetic peptides derived from Box A region of Tob/BTG family proteins against the amyloid-β fragment peptides, Integr. Mol. Med., 6, 1–4 (2019)
4) M. Crous-Bou, C. Minguillon, N. Gramunt, J. L. Molinuevo, Alzheimer's disease prevention: from risk factors to early intervention. Alzheimers. Res. Ther., 9, 71 (2017)
5) W. Jason, B. Andrew, Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res., 7, F1000 Faculty Rev-1161 (2018)
6) R. Li, X. Wang, K. Lawler, S. Garg, Q. Bai, J. Alty, Applications of artificial intelligence to aid early detection of dementia: A scoping review on current capabilities and future directions. J. Biomed. Inform., 127, 104030 (2022)
7) E. Karran, M. Mercken, B. De Strooper, The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics, Nat. Rev. Drug Discov, 10, 698–712 (2011)
8) M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J. I. Elliott, W. E. Van Nostrand, S. O. Smith, Structural conversion of neurotoxic amyloid-β 1-42 oligomers to fibrils. Nat. Struct. Mol. Biol., 17, 561–567 (2010)
9) I. W. Hamley, The amyloid beta peptide: a chemist’s perspective. role in Alzheimer’s and fibrillization, Chem. Rev., 112, 5147–5192 (2012)
10) T. Lührs, C. Ritter, M. Adrian, D. Riek-Loher, B. Bohrmann, H. Döbeli, D. Schubert, R. Riek, 3D structure of Alzheimer’s amyloid-β (1-42) fibrils, Proc. Natl. Acad. Sci. USA., 102, 17342–17347 (2005)
11) S. A. Kotler, J. R. Brender, S. Vivekanandan, Y. Suzuki, K. Yamamoto, M. Monette, J. Krishnamoorthy, P. Walsh, M. Cauble, M. M. B. Holl, E. N. G. Marsh, A. Ramamoorthy High-resolution NMR characterization of low abundance oligomers of amyloid-β without purification. Sci. Rep., 5, 1–12 (2015)
12) S. A. Kotler, P. Walsh, J. R. Brender, A. Ramamoorthy, Differences between amyloid- β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer’s disease, Chem. Soc. Rev., 43, 6692–6700 (2014)
13) R. S. Doody, R. G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, K. Kieburtz, R. Raman, X. Sun, P. S. Aisen, E. Siemers, H. Liu-Seifert, R. Mohs, Phase 3 trials of solanezumab for mild-to-moderate alzheimer’s disease, N. Engl. J. Med., 370, 311– 321 (2014)
14) T. Sato, P. Kienlen-Campard, M. Ahmed, W. Liu, H. Li, J. I. Elliott, S. Aimoto, S. N. Constantinescu, J. N. Octave, S. O. Smith, Inhibitors of amyloid toxicity based on β- sheet packing of Aβ40 and Aβ42. Biochemistry, 45, 5503–5516 (2006)
15) X. Sun, W. D. Chen, Y. D.Wang, The key peptide in the pathogenesis of Alzheimer’s disease. Front Pharmacol., 6, 221 (2015)
16) W. P. Esler, M. S. Wolfe, A portrait of Alzheimer secretases - New features and familiar faces, Science, 293, 1449–1454 (2001).
17) K. Garai, A. E. Posey, X. Li, J. N. Buxbaum, R. V. Pappu, Inhibition of amyloid beta fibril formation by monomeric human transthyretin, Protein Sci., 27, 1252–1261 (2018)
18) S. J. C. Lee, E. Nam, H. J. Lee, M. G. Savelieff, M. H. Lim, Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors, Chem. Soc. Rev., 46, 310–323 (2015)
19) G. S. Winkler, The mammalian anti-proliferative BTG/Tob protein family, J. Cell. Physiol., 222, 66–72 (2010)
20) U. Schulze-Topphoff, S. Casazza, M. Varrin-Doyer, K. Pekarek, R. A. Sobel, S. L. Hauser, J. R. Oksenberg, S. S. Zamvil, S. E. Baranzini, Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity, J. Exp. Med., 210, 1301–1309 (2013)
21) Y. Chen, C. Wang, J. Wu, L. Li, BTG/Tob family members Tob1 and Tob2 inhibit proliferation of mouse embryonic stem cells via Id3 mRNA degradation, Biochem. Biophys. Res. Commun., 462, 208–214 (2015)
22) X. Yang, M. Morita, H. Wang, T. Suzuki, W. Yang, Y. Luo, C. Zhao, Y. Yu, M. Bartlam, T. Yamamoto, Z. Rao, Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity, Nucleic Acids Res., 36, 6872–6881 (2008)
23) S. Matsuda, J. Kawamura-Tsuzuku, M. Ohsugi, M. Yoshida, M. Emi, Y. Nakamura, M. Onda, Y. Yoshida, A. Nishiyama, T. Yamamoto, Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene., 12, 705– 718 (1996).
24) M. Horiuchi, K. Takeuchi, N. Noda, N. Muroya, T. Suzuki, T. Nakamura, J. Kawamura-Tsuzuku, K. Takahasi, T. Yamamoto, F. Inagaki, Structural basis for the antiproliferative activity of the Tob-hCaf1 complex, J. Biol. Chem., 284, 13244– 13255 (2009)
25) Y. Yoshida, S. Matsuda, N. Ikematsu, J. Kawamura-Tsuzuku, J. Inazawa, H. Umemori, T. Yamamoto, ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system, Oncogene., 16, 2687– 2693 (1998)
26) Y. H. Ou, P. H. Chung, F. F. Hsu, T. P. Sun, W. Y. Chang, S. Y. Shieh, The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1, EMBO J., 26, 3968–3980 (2007)
27) Y. C. Cheng, P. H. Chen, H. Y. Chiang, C. S. Suen, M. J. Hwang, T. Y. Lin, H. C. Yang, W. C. Lin, P. L. Lai, S. Y. Shieh, Candidate tumor suppressor B-cell translocation gene 3 impedes neoplastic progression by suppression of AKT, Cell Death Dis., 6, e1584 (2015)
28) C. Lv, H. Wang, Y. Tong, H. Yin, D. Wang, Z. Yan, Y. Liang, D. Wu, Q. Su, The function of BTG3 in colorectal cancer cells and its possible signaling pathway, J. Cancer Res. Clin. Oncol., 144, 295–308 (2018)
29) M. Yoneda, T. Suzuki, T. Nakamura, R. Ajima, Y. Yoshida, S. Kakuta, K. Sudo, Y. Iwakura, M. Shibutani, K. Mitsumori, J. Yokota, T. Yamamoto, Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma, Cancer Sci., 100, 225–232 (2009)
30) W. F. Gou, X. F. Yang, D. F. Shen, S. Zhao, Y. P. Liu, H. Z. Sun, Y. Takano, R. J. Su, J. S. Luo, H. C. Zheng, The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy, Oncotarget, 6, 19841–19867 (2015)
31) M. Taniguchi, K. Matsuura, R. Nakamura, A. Kojima, M. Konishi, T. Akizawa, MMP-7 cleaves amyloid β fragment peptides and copper ion inhibits the degradation, Biometals, 30, 797–807 (2017)
32) M. M. Condron, B. H. Monien, G. Bitan, Synthesis and purification of highly hydrophobic peptides derived from the C-Terminus of Amyloid β-Protein, Open Biotechnol. J., 2, 87–93 (2008)
33) M. Yagi-Utsumi, K. Kato, K. Nishimura, Membrane-induced dichotomous conformation of amyloid β with the disordered n-Terminal segment followed by the stable c-Terminal β Structure, PLoS One, 11, e0146405 (2016)
34) T. D. Do, N. E. LaPointe, R. Nelson, P. Krotee, E. Y. Hayden, B. Ulrich, S. Quan, S. C. Feinstein, D. B. Teplow, D. Eisenberg, J. E. Shea, M. T. Bowers, Amyloid β- Protein C-terminal fragments: Formation of cylindrins and β-barrels HHS public access, J. Am. Chem. Soc., 138, 549–557 (2016)
35) A. K. Surin, E. I. Grigorashvili, M. Y. Suvorina, O. M. Selivanova, O. V. Galzitskaya, Determination of regions involved in amyloid fibril formation for Aβ (1–40) peptide, Biochemistry (Mosc), 81, 762—769 (2016)
36) I. V. Kurochkin, S. Goto, Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme, FEBS Lett., 345, 33–37 (1997).
37) W. Farris, S. Mansourian, Y. Chang, L. Lindsley, E. A. Eckman, M. P. Frosch, C. B. Eckman, R. E. Tanzi, D. J. Selkoe, S. Guenette, Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc. Natl. Acad. Sci. USA., 100, 4162–4167 (2003)
38) M. Hernandez-Guillamon, S. Mawhirt, S. Blais, J. Montaner, T. A. Neubert, A. Rostagno, J. Ghiso, Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9, J. Biol. Chem., 290, 15078–15091 (2015)
39) L. Morelli, R. Llovera, S. Ibendahl, E.M. Castaño, The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidosis, Neurochem. Res., 27, 1387–1399 (2002)
40) N. N. Nalivaeva, C. Beckett, N. D. Belyaev, A. J. Turner, Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease ?, J. Neurochem., 120, 167–185 (2012)
41) T. D. Shropshire, J. Reifert, S. Rajagopalan, D. Baker, S. C. Feinstein, P. S. Daugherty, Amyloid β peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from Aβ-mediated toxicity in vitro, Biol. Chem., 395, 109–118 (2014)
42) K. Kidana, T. Tatebe, K. Ito, N. Hara, A. Kakita, T. Saito, S. Takatori, Y. Ouchi, T. Ikeuchi, M. Makino, T. C. Saido, M. Akishita, T. Iwatsubo, Y. Hori, T. Tomita, Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice, EMBO Mol. Med., 10, e8184 (2018)
43) N. Iwata, S. Tsubuki, Y. Takaki, K. Watanabe, M. Sekiguchi, E. Hosoki, M. Kawashima-Morishima, H. J. Lee, E. Hama, Y. Sekine-Aizawa, T. C. Saido, Identification of the major Abeta1-42 degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition, Nat. Med., 6, 143–150 (2000)
44) N. Iwata, S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N. P. Gerard, C. Gerard, E. Hama, H. J. Lee, T. C. Saido, Metabolic regulation of brain Aβ by neprilysin, Science, 292, 50–52 (2001)
45) H. Kanemitsu, T. Tomiyama, H. Mori, Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form, Neurosci. Lett., 350, 113–116 (2003)
46) K. G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J. C. Morris, K. E. Yarasheski, R. J. Bateman, Decreased clearance of CNS β-amyloid in Alzheimer's disease, Science, 330, 1774 (2010)
47) J. R. Cirrito, J. E. Kang, J. Lee, F. R. Stewart, D. K. Verges, L. M. Silverio, G. Bu, S. Mennerick, D. M. Holtzman, Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo, Neuron, 58, 42–51 (2008)
48) R. Kino, T. Araya, T. Arai, Y. Sohma, M. Kanai, Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif, Bioorg. Med. Chem. Lett., 25, 2972–2975 (2015)
49) J. Kumar, R. Namsechi, V.L. Sim, Structure-based peptide design to modulate amyloid beta aggregation and reduce cytotoxicity, PLoS One, 10, 1–18 (2015)
50) L. M. Young, J. C. Saunders, R. A. Mahood, C. H. Revill, R. J. Foster, L. H. Tu, D. P. Raleigh, S. E. Radford, A. E. Ashcroft, Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry, Nat. Chem., 7, 73–81 (2015).
51) P. J. Crouch, D. J. Tew, T. Du, D. N. Nguyen, A. Caragounis, G. Filiz, R. E. Blake, I. A. Trounce, C. P. W. Soon, K. Laughton, K. A. Perez, Q. X. Li, R. A. Cherny, C. L. Masters, K. J. Barnham, A. R. White, Restored degradation of the Alzheimer’s amyloid-β peptide by targeting amyloid formation, J. Neurochem., 108, 1198–1207 (2009)
52) T. Storr, M. Merkel, G. X. Song-Zhao, L. E. Scott, D. E. Green, M. L. Bowen, K. H. Thompson, B. O. Patrick, H. J. Schugar, C. Orvig, Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer’s therapy, J. Am. Chem. Soc., 129, 7453–7463 (2007)
53) J. Cummings, G. Lee, K. Zhong, J. Fonseca, K. Taghva, Alzheimer’s disease drug development pipeline: 2021, Alzheimers Dement. (N. Y.), 7, e12179 (2021)
54) S. M. de la Monte, M. Tong, Brain metabolic dysfunction at the core of Alzheimer’s disease, Biochem. Pharmacol., 88, 548–559 (2014)
55) F. G. De Felice, M. V. Lourenco, S. T. Ferreira, How does brain insulin resistance develop in Alzheimer’s disease ?, Alzheimer's Dementia, 10, 26–32 (2014)
56) F. G. De Felice, M. N. Vieira, T. R. Bomfim, H. Decker, P. T. Velasco, M. P. Lambert, K. L. Viola, W. Q. Zhao, S. T. Ferreira, W. L. Klein, Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers, Proc. Natl. Acad. Sci. USA., 106, 1971–1976 (2009)
57) L. J. Young, C. E. Barrett, Can oxytocin treat autism ?: We are still at an early stage of assessing oxytocin-based therapy for autism spectrum disorders, Science, 347, 825–826 (2015)
58) M. M. DeMayo, L. J. Young, I. B. Hickie, Y. J. C. Song, A. J. Guastella, Circuits for social learning: A unified model and application to Autism Spectrum Disorder, Neurosci. Biobehav. Rev., 107, 388–398 (2019)
59) O. Gartziandia, S. P. Egusquiaguirre, J. Bianco, J. L. Pedraz, M. Igartua, R. M. Hernandez, A. Beloqui, Nanoparticle transport across in vitro olfactory cell monolayers, Int. J. Pharm., 499, 81–89 (2016)
60) K. Singh, Z. Ahmad, P. Shakya, V. A. Ansari, A. Kumar, M. Zishan, M. Arif, Nano formulation: A novel approach for nose to brain drug delivery, J. Chem. Pharm. Res., 8, 208–215 (2016)
61) A. D. Kulkarni, Y. H. Vanjari, K. H. Sancheti, V. S. Belgamwar, S. J. Surana, C. V. Pardeshi, Nanotechnology-mediated nose to brain drug delivery for Parkinson’s disease: A mini review, J. Drug Target., 23, 775–788 (2015)
62) T. Sakane, M. Akizuki, S. Yamashita, T. Nadai, M. Hashida, H. Sezaki, Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity, J. Pharm. Pharmacol., 43, 449–451 (1991)
63) J. Sousa, G. Alves, P. Oliveira, A. Fortuna, A. Falcao, Intranasal delivery of ciprofloxacin to rats: A topical approach using a thermoreversible in situ gel, Eur. J. Pharm. Sci., 97, 30−37 (2017)
64) G. Rassu, E. Soddu, M. Cossu, A. Brundu, G. Cerri, N. Marchetti, L. Ferraro, R. F. Regan, P. Giunchedi, E. Gavini, A. Dalpiaz, Solid microparticles based on chitosan or methyl-βcyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate, J. Control. Release, 201, 68−77 (2015)
65) L. W. Fan, K. Carter, A. Bhatt, Y. Pang, Rapid transport of insulin to the brain following intranasal administration in rats, Neural Regener. Res., 14, 1046−1051 (2019)
66) R. G. Thorne, L. R. Hanson, T. M. Ross, D. Tung, W. H. Frey, 2nd Delivery of interferon-beta to the monkey nervous system following intranasal administration, Neuroscience, 152, 785–797 (2008)
67) S. M. Freeman, S. Samineni, P. C. Allen, D. Stockinger, K. L. Bales, G. G. Hwa, J. A. Roberts, Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques, Psychoneuroendocrinology, 66, 185–194 (2016)
68) M. R. Lee, K. B. Scheidweiler, X. X. Diao, F. Akhlaghi, A. Cummins, M. A. Huestis, L. Leggio, B. B. Averbeck, Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay, Mol. Psychiatry, 23, 115–122 (2018)
69) F. Erdő, L. A. Bors, D. Farkas, Á. Bajza, S. Gizurarson, Evaluation of intranasal delivery route of drug administration for brain targeting, Brain Res. Bull., 143, 155– 170 (2018)
70) W. H. Frey II, J. Liu, X. Chen, R. G. Thorne, J. R. Fawcett, T. A. Ala, Y. E. Rahman, Delivery of 125 I-NGF to the Brain via the Olfactory Route. Drug Deliv., 4, 87–92 (1997)
71) M. H. Zada, M. Kubek, W. Khan, A. Kumar, A. Domb, Dispersible hydrolytically sensitive nanoparticles for nasal delivery of thyrotropin releasing hormone (TRH). J. Control. Release, 295, 278–289 (2019)
72) J. C. Garcia-Rodriguez, I. Sosa-Teste, The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. Sci. World J., 9, 970–981 (2009)
73) N. Nonaka, S. A. Farr, H. Kageyama, S. Shioda, W. A. Banks, Delivery of galanin- like peptide to the brain: Targeting with intranasal delivery and cyclodextrins. J. Pharmacol. Exp. Ther., 325, 513–519 (2008)
74) R. G. Thorne, L. R. Hanson, T. M. Ross, D. Tung, W. H. Frey Ⅱ, Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience, 152, 785–797 (2008)
75) J. P. Yang, H. J. Liu, S. M. Cheng, Z. L. Wang, X. Cheng, H. X. Yu, X. F. Liu, Direct transport of VEGF from the nasal cavity to brain. Neurosci. Lett., 449, 108–111 (2009)
76) S. V. Dhuria, L. R. Hanson, W. H. Frey II, Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J. Pharm. Sci., 98, 2501–2515 (2009)
77) J. G. Veening, B. Olivier, Intranasal administration of oxytocin: Behavioral and clinical effects, a review. Neurosci. Biobehav. Rev., 37, 1445–1465 (2013)
78) I. Gozes, E. Giladi, A. Pinhasov, A. Bardea, D. E. Brenneman, Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther., 293, 1091–1098 (2000)
79) R. N. Alcalay, E. Giladi, C. G. Pick, I. Gozes, Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett., 361, 128–131 (2004)
80) A. Tanaka, T. Furubayashi, M. Arai, D. Inoue, S. Kimura, A. Kiriyama, K. Kusamori, H. Katsumi, R. Yutani, T. Sakane, A. Yamamoto, Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application, Mol. Pharm., 15, 1105–1111 (2018)
81) A. Tanaka, K. Takayama, T. Furubayashi, K. Mori, Y. Takemura, M. Amano, C. Maeda, D. Inoue, S. Kimura, A. Kiriyama, H. Katsumi, M. Miyazato, K. Kangawa, T. Sakane, Y. Hayashi, A. Yamamoto, Transnasal Delivery of the Peptide Agonist Specific to Neuromedin-U Receptor 2 to the Brain for the Treatment of Obesity, Mol. Pharm., 17, 32–39, (2020)
82) Y. Sasaki, H. N. J. Wagner, Measurement of the distribution of cardiac output in unanesthetized rats, J. Appl. Physiol., 30, 879–884 (1971)
83) T. P. Crowe, M. H. W. Greenlee, A. G. Kanthasamy, W. H. Hsu, Mechanism of intranasal drug delivery directly to the brain, Life Sci., 195, 44–52 (2018)
84) K. Buchner, D. Seitz-Tutter, K. Schönitzer, D. G. Weiss, A quantitative study of anterograde and retrograde axonal transport of exogenous proteins in olfactory nerve C-fibers, Neuroscience, 22, 697–707 (1987)
85) J. J. Lochhead, R. G. Thorne, Intranasal delivery of biologics to the central nervous system, Adv. Drug Deliv. Rev., 64, 614–628 (2012)
86) N. Hada, W. J. Netzer, F. Belhassan, L. P. Wennogle, S. Gizurarson, Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation, Eur. J. Pharm. Sci., 102, 46–54 (2017)
87) J. J. Iliff, H. Lee, M. Yu, T. Feng, J. Logan, M. Nedergaard, H. Benveniste, Brain- wide pathway for waste clearance captured by contrast-enhanced MRI, J. Clin. Investig., 123, 1299–1309 (2013)
88) N. A. Jessen, A. S. F. Munk, I. Lundgaard, M. Nedergaard, The glymphatic system: A beginner’s guide, Neurochem. Res., 40, 2583–2599 (2015)
89) J. Sevigny, P. Chiao, T. Bussière, P. H. Weinreb, L. Williams, M. Maier, A. Sandrock, The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease, Nature, 537, 50–56 (2016)
90) J. Lu, H. Xu, J. Xia, J. Ma, J. Xu, Y. Li and J. Feng, D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics, Front. Microbiol., 11, 563030 (2020)
91) N. Kamei, N. Okada, T. Ikeda, H. Choi, Y. Fujiwara, H. Okumura & M. Takeda- Morishita, Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction, Sci. Rep., 8, 17641 (2018)
92) H. Shinichiro, Y. Takatsuka, M. Tai, M. Hiroyuki, Absorption of drugs from the nasal mucosa of rat, Int. J. Pharm., 7, 317–325 (1981)
93) M. Fukuda, T. Kanazawa, S. Iioka, T. Oguma, R. Iwasa, S. Masuoka, T. Suzuki, Quantitative analysis of inulin distribution in the brain focused on nose-to-brain route via olfactory epithelium by reverse esophageal cannulation. J. Control. Release, 332, 493–501 (2021)
94) M. J. Dudek, J. W. Ponder, Accurate modeling of the intramolecular electrostatic energy of proteins, J. Comput. Chem., 16, 791–816 (1995)